NFKB1 and cancer: Since its discovery by Ranjan Sen and David Baltimore in 1986, the nuclear factor κB (NF-κB) transcription-factor pathway has been the focus of intense investigation, reflecting its ubiquitous nature and pivotal roles in essential physiological processes, such as the coordination of immune and inflammatory responses and cell survival, and the etiopathogenesis of a myriad of human diseases, including cancer [1,2,3,4,5,6].